Selected Publications
Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer.
Tsongalis et al.,
Am J Clin Pathol. 2020 Jul 7:154(2):266-276
PMID: 32525522
Targetable molecular alterations in congenital glioblastoma.
Gilani A, Donson A, Davies KD, Whiteway SL, Lake J, DeSisto J, Hoffman L, Foreman NK, Kleinschmidt-DeMasters BK, Green AL.
J Neurooncol. 2020 Jan;146(2):247-252. doi: 10.1007/s11060-019-03377-8
PMID: 31875306
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC.
Clin Lung Cancer. 2020 May;21(3):e191-e204. doi: 10.1016/j.cllc.2019.11.008
PMID: 31859066
Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.
Lake JA, Donson AM, Prince E, Davies KD, Nellan A, Green AL, Mulcahy Levy J, Dorris K, Vibhakar R, Hankinson TC, Foreman NK, Ewalt MD, Kleinschmidt-DeMasters BK, Hoffman LM, Gilani A.
Pediatr Blood Cancer. 2020 Jan;67(1):e28028. doi: 10.1002/pbc.28028
PMID: 31595628
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing.
Seager M, Aisner DL, Davies KD.
J Vis Exp. 2019 Jul 5;(149):10.3791/59895. doi: 10.3791/59895.
PMID: 31329176
The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement
Willberber AC, McMahon B, Ewalt MD
Leuk Lymphoma. 2019 Apr;60(4):1095-1097. doi: 10.1080/10428194.2018.1516038
PMID: 30277124
Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR.
Gynecol Oncol. 2019 Jun;153(3):517-520. doi: 10.1016/j.ygyno.2019.03.100
PMID: 30910249
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, Aisner DL.
J Thorac Oncol. 2019 Apr;14(4):737-741. doi: 10.1016/j.jtho.2018.12.020. Epub 2019 Jan 9.
PMID: 30639620
Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Davies KD, Le AT, Sheren J, Nijmeh H, Gowan K, Jones KL, Varella-Garcia M, Aisner DL, Doebele RC.
J Thorac Oncol. 2018 Oct;13(10):1474-1482. doi: 10.1016/j.jtho.2018.05.041. Epub 2018 Jun 20.
PMID: 29935306
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.
Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452.
PMID: 29636358
Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion.
Davies KD, Ng TL, Estrada-Bernal A, Le AT, Ennever PR, Camidge DR, Doebele RC, Aisner DL.
JCO Precis Oncol. 2017;2017(1):10.1200/PO.17.00117. doi: 10.1200/PO.17.00117. Epub 2017 Aug 29.
PMID: 29527595
Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next-Generation Sequencing Bioinformatics and Variant Interpretation.
Davies KD, Farooqi MS, Gruidl M, Hill CE, Woolworth-Hirschhorn J, Jones H, Jones KL, Magliocco A, Mitui M, O'Neill PH, O'Rourke R, Patel NM, Qin D, Ramos E, Rossi MR, Schneider TM, Smith GH, Zhang L, Park JY, Aisner DL.
J Mol Diagn. 2016 Jul;18(4):572-9. doi: 10.1016/j.jmoldx.2016.03.002
PMID: 27155050